Traitements3programmes
Essais1liés
Publications6liées
SourceDBlocale

Traitements

3
MoléculeIndication / populationPhaseObjectifPaysRésultat
IPX066This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease. Parkinson Phase 3 À vérifier United States, Canada, France, Germany, Poland, Romania, Spain, Ukraine À vérifier
IR CD-LDThis is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease. Parkinson Phase 3 À vérifier United States, Canada, France, Germany, Poland, Romania, Spain, Ukraine À vérifier
IPX066This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease. Parkinson Phase 3 À vérifier United States, Canada, France, Germany, Poland, Romania, Spain, Ukraine À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
IPX066 Parkinson Phase 3 NCT00974974 A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). COMPLETED

Publications

6
MoléculeIndication / populationTitreJournalDate
IR CD-LD Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®). Parkinsonism & related disorders
IPX066 Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism & related disorders
IR CD-LD How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's disease. Clinical parkinsonism & related disorders
IR CD-LD Efficacy and safety of IPX203 in Parkinson's patients: a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
IPX066 Plant-Based Therapies to Ameliorate Neuroinflammation in Parkinson's Disease, Alzheimer's Disease, and Epilepsy: A Narrative Review. Chemistry & biodiversity
IPX066 Treatment strategies for motor fluctuations in Parkinson's disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America. Frontiers in pharmacology